Your browser doesn't support javascript.
loading
Molecular Characterization of Multifocal Granular Cell Tumors.
Dehner, Carina A; Schroeder, Molly C; Lyu, Yang; Bell, Robert; Borcherding, Dana C; Moon, Tyler; Hirbe, Angela; Chrisinger, John S A.
Affiliation
  • Dehner CA; Department of Pathology and Immunology.
  • Schroeder MC; Department of Pathology and Immunology.
  • Lyu Y; Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.
  • Bell R; Department of Pathology and Immunology.
  • Borcherding DC; Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.
  • Moon T; University Hospitals Cleveland Medical Center Department of Orthopedic Surgery, Cleveland, OH.
  • Hirbe A; Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO.
  • Chrisinger JSA; Department of Pathology and Immunology.
Am J Surg Pathol ; 47(3): 326-332, 2023 03 01.
Article in En | MEDLINE | ID: mdl-36534754
Granular cell tumors (GrCT) were recently found to be driven by inactivating mutations in vacuolar H + -ATPase (V-ATPase) genes, most frequently ATP6AP1 and ATP6AP2 . Multifocal presentation is present in ~10% of cases; however, the relationship between multifocal tumors in a given patient has not been elucidated. We hypothesized that benign-appearing multifocal GrCT are molecularly distinct whereas paired primary and metastatic malignant GrCT share identical mutations. To test this, we conducted targeted next-generation sequencing of the V-ATPase genes in multifocal GrCT and whole exome and Sanger sequencing in paired primary and metastatic malignant GrCT. Thirteen patients with≥2 GrCT were identified (total of 43 tumors). Forty-two tumors were successfully sequenced. Tumors showed somatic mutations in 3 of the 10 targeted genes in 32 of 42 samples (76%). Twenty tumors showed mutations in ATP6AP1 (48%), 10 tumors had mutations in ATP6AP2 (24%), and 2 tumors showed mutations in ATP6V0A4 (5%). Predicted loss-of-function mutations were found in ATP6AP1 in 17 tumors (40%), in ATP6AP2 in 10 tumors (24%), and in ATP6V0A4 in 1 tumor (2%). In 8 patients, mutually exclusive mutations were detected in at least 2 tumors per patient. Two patients were identified with malignant GrCT with material available from both primary and metastatic sites. Identical frameshift insertions were found in ATP6AP1 in 1 case and the second case showed identical nonsense mutations in ATP6AP1 . In conclusion, multifocal GrCT within an individual patient are molecularly distinct, while paired primary and metastatic GrCT share identical mutations.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Granular Cell Tumor / Vacuolar Proton-Translocating ATPases Limits: Humans Language: En Journal: Am J Surg Pathol Year: 2023 Document type: Article Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Granular Cell Tumor / Vacuolar Proton-Translocating ATPases Limits: Humans Language: En Journal: Am J Surg Pathol Year: 2023 Document type: Article Country of publication: